Secondary Logo

Institutional members access full text with Ovid®

The Psychopharmacology Algorithm Project at The Harvard South Shore Program: An Update on Generalized Social Anxiety Disorder

Osser, David N. MD; Dunlop, Lance R. MD

Section Editor(s): Janicak, Philip G. MD, Editor

doi: 10.1097/01.IDT.0000391328.04097.1e

Dr. Osser is Associate Professor of Psychiatry, Harvard Medical School, 150 Winding River Road, Needham, MA 02492, E-mail:; and Dr. Dunlop is Acting Medical Director, Cambria County Mental Health/Mental Retardation Clinic, Johnstown, PA.

All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity.

The authors have disclosed that the use of citalopram, escitalopram, fluoxetine, phenelzine, clonazepam, alprazolam, buspirone, nefazodone, gabapentin, quetiapine, risperidone, pregabalin, and tiagabine for treatment of social anxiety disorder has not been approved by the U.S. Food and Drug Adminstration.

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on November 30, 2011.

© 2010 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website